Modality
Gene Therapy
MOA
BETi
Target
TIGIT
Pathway
Hedgehog
IPF
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
Mar 2018
→ Feb 2029
Phase 2Current
NCT04984789
1,457 pts·IPF
2018-03→2029-02·Not yet recruiting
1,457 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-062.9y awayPh2 Data· IPF
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Not yet…
Catalysts
Ph2 Data
2029-02-06 · 2.9y away
IPF
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04984789 | Phase 2 | IPF | Not yet recr... | 1457 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |